literature

Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China.

PMID: 21959623 2011 Medical science monitor

Discussion: Other mutations and mixed combinations were also observed (rtM204I+rtV207M/L, rtM204I+rtV173L, rtM204I+rtS213T, rtM204V+rtL180M+rtV173L/M, rtM204V+rtL180M+rt

PMID: 22053371 2011 Zhonghua gan zang bing za zhi

Abstract: The rtM204V-rtL180M mutations were more frequently found in subgenotype B2 than in subgenotype C2 while the rtM204V-rtL180M-rtV173L mutations were more associated with subgenotype C2 (P < 0.01).

Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.

PMID: 22195774 2011 BMC research notes

Abstract: One patient showed the M204V+ L180M+ V173L+ triple mutation associated with a vaccine escape phenotype, which could be of public health concern in a country with a national HBV vaccination programme.

Result: The virus from patient 12 had an S219A mutation, which reverted to the wild-type when 3TC resistance mutations V173L, L180M and Table: V173L

Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies.

PMID: 22224083 2011 Hepatitis monthly

Result: Four different LAM resistance patterns were identified in 84 out of 194 patients (43%): baseline primary mutation (rtM204I/V, n = 26), primary mutation with the compensatory mutations rtL80I/V (n = 16) or rtL180M (n = 24), triple mutant (rtM204I/V + rtV173L + rtL180M or rtA194G, n = 12), and the single mutation rtL180M (n = 6).

Result: The observed patterns of LdT resistance included baseline primary mutati

Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations.

PMID: 20119580 2010 Journal of Korean medical science

Discussion: The LMV-resistant polymerase mutation, rtV173L (sE164D), has been reported to reduce the antigenicity of HBsAg.

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

PMID: 20164224 2010 Journal of virology

Abstract: A quadruple mutant (L129M, V173L, M204I, and H337N) was identified that conferred greater replicative ability and strong resistance to both CLV and lamivudine.

Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.

PMID: 20332649 2010 Intervirology

Abstract: PC mutation, the absence of compensatory mutations (rtL80I/V or rtV173L), and a decrease in serum hepatitis B virus (HBV) DNA by 3 log or greater at 6 months were independent predictors of virologic response.

Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.

PMID: 20377434 2010 AIDS patient care and STDs

Abstract: All 19 patients with HBV-DR had lamivudine resistance with the mutations as follows: M204V/I (95%), L180M/A181T (95%), L80V/I (47%), V173L (32%), and N236T (21%).

[Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine].

PMID: 20380793 2010 Zhonghua gan zang bing za zhi

Abstract: The overall incidence rate of A181V/T mutation in genotype C (5.3%) was significantly higher than that in genotype B (0.4%) (x2=12.23, P less than 0.01), but the incidence rate of M204I/V, L180M, T184A/G/I/S, S202G/I and V173L mutations was not significantly different between genotype B and C (each P more than 0.05).

Infectivity and vaccination efficacy studies in animal models of HBV S and pol gene mutants.

PMID: 20516568 2010 Antiviral therapy

Abstract: Infectious HBV wild-type and mutant clones were produced in vitro with three mutations in pol (rtV173L plus rtL180M plus rtM204V) or with a single mutation in the S gene (sG145R) and inoculated in treatment-naive chimpanzees.